cyberknife

CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance

This regimen of stereotactic CyberKnife monotherapy for low- to intermediate-risk prostate cancer with excellent dose coverage of the prostate was well tolerated. Data collection is ongoing for further assessment of toxicity and PSA response.

CyberKnife robotic radiosurgery system for tumor treatment

The CyberKnife (Accuray, Inc., Sunnyvale, CA, USA) is one of few systems capable of delivering radiosurgery with exquisite accuracy to tumors, cancers and other conditions throughout the body.

CyberKnife radiosurgery in the treatment of complex skull base tumors: analysis of treatment planning parameters

Data indicate that CyberKnife treatment plans with excellent homogeneity, conformity and percent target coverage can be obtained for complex skull base tumors.

CyberKnife radiosurgery for stage I lung cancer: results at 36 months

Image-guided robotic stereotactic radiosurgery of lung tumors with CyberKnife(R) achieves excellent rates of local disease control with limited toxicity to surrounding tissues and, in many cases, might be curative for patients for whom surgery is not an option.

CyberKnife radiosurgery for prostate cancer

Recently, new data have emerged that show promising outcomes with minimal toxicity for CyberKnife SBRT of prostate cancer.

Partial Breast Irradiation After Lumpectomy

CyberKnife radiosurgery, in conjunction with Synchrony® Respiratory Tracking, precisely delivers the prescription dose over a much shorter course of treatment than conventional radiotherapy.

Pages